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Short and midterm results with minimally invasive
endovascular repair of acute and chronic thoracic
aortic pathology
Katherine E. Brown, DO, Mark K. Eskandari, MD, Jon S. Matsumura, MD, Heron Rodriguez, MD, and
Mark D. Morasch, MD, Chicago, Ill
Objectives: Endovascular management of both acute and chronic thoracic aortic pathology has emerged as an alternative
to open surgery. We reviewed our single center experience with endovascular devices for the treatment of thoracic aortic
pathology.
Methods: Between April 2000 and October 2007, 116 thoracic aortic stent grafts were placed to treat a variety of acute or
chronic thoracic aortic lesions. Thirty-five percent of the cases were performed emergently. Sixty-five percent of the
patients were male; the average age was 63.9 years (range 20-93 years). Indications for treatment were chronic
degenerative aneurysms (n  70), traumatic aortic disruption (n  20), complicated dissection, intramural hematoma, or
penetrating aortic ulcer (n  14), pseudoaneurysm (n  10), and Diverticulum of Kommerell (n  2). Arch vessel
revascularization (n  32) or mesenteric debranching (n  7) was performed in select cases. Devices used were
industry-approved thoracic aortic devices (n  80), aortic cuff extenders (n  19), or custom made by the surgeon (n 
17).
Results: The 30-day death, stroke and paraplegia/paresis rates were 5.2%, 8.6%, and 2.6%, respectively. Arterial access
complications requiring immediate operative repair occurred at a rate of 11.2% (n  13). The endoleak rate requiring
repeat intervention was 6.9% (n  8). The delayed graft infection rate was 5.2% (n  6), with four of these cases resulting
in death. The mean follow-up is 15 months (range 1-78 months). Computed tomography angiograms were performed at
1, 6, and 12 months following the index procedure, and yearly thereafter.
Conclusions: Endovascular therapy for acute and chronic thoracic aortic pathology is a viable alternative to open surgery
with comparable operative morbidity and mortality. Midterm results suggest that endografts are durable, but require
more secondary interventions and imaging surveillance than open reconstruction. ( J Vasc Surg 2008;47:714-23.)The traditional operative approach to the treatment of
thoracic disease remains a highly morbid, and often mortal,
procedure for elderly patients with pre-existing illnesses.
Advances in endovascular technology used in the treatment
of abdominal aortic aneurysms have been applied to tho-
racic aortic pathologies. Thoracic endovascular repair is
now a viable alternative to open thoracic aortic reconstruc-
tion.1-4 From the early use of custom-made stent grafts in
1994, through the development of industry-designed and
FDA-approved thoracic aortic endografts, a number of
significant advances have been made.1 Despite this techni-
cal revolution there remains significant risk associated with
minimally invasive treatment of the thoracic aorta. Current
reports in literature describe morbidity and mortality rates
ranging from 2% to 28%.2-5 Furthermore, reports suggest
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714that secondary interventions are frequently required for
patients treated with these devices.6-8 We sought to review
the early and midterm results from our single center with
the use of custom-made, as well as industry-designed,
endovascular devices for the treatment of acute or chronic
thoracic aortic pathology.
PATIENTS AND METHODS
A retrospective review was conducted of all thoracic
endovascular aortic repairs (TEVAR) performed between
April 2000 and October 2007. There were a total of 116
primary TEVAR procedures performed on 115 patients at
Northwestern Memorial Hospital and the Lakeside and
Jesse Brown Veteran Administration Medical Centers.
Data collection was performed according to approved In-
stitutional Review Board protocols. A total of 28 of the
thoracic aortic aneurysm patients were enrolled in a clinical
trial involving the use of industry devices for the endovas-
cular treatment of thoracic aortic aneurysms.
Indications for treatment included asymptomatic de-
generative thoracic aneurysms (DTA), aortic dissections
with chronic aneurysmal change 5.5 cm or thoracic an-
eurysm rupture (n  70; 60.3%); traumatic aortic disrup-
tion (n  20; 17.2%); anastomotic pseudoaneurysm (n 
10; 8.6%); acute complicated dissection (n  6; 5.2%),
penetrating aortic ulcer (n  4; 3.4%), intramural hema-
toma (n  4; 3.4%), and Diverticulum of Kommerell (n 
2; 1.7%) (Table I). Emergency procedures were defined as
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the institution.
All patients underwent computed tomography angio-
gram (CTA) with or without preoperative digital subtrac-
tion angiography to assess the suitability of the thoracic
aorta for endovascular treatment. Proximal and distal land-
ing zones of at least 2 cm were required for suitable fixation
of the endograft. Arch or mesenteric artery revasculariza-
tion procedures were performed ahead of time or during
the index procedure in 41 (35.3%) cases to allow for
adequate proximal or distal fixation when indicated and
time permitted.
Procedural details and devices. All procedures were
performed in an operating suite equipped with a fixed
fluoroscopic unit (Philips V5000, Nederland, BV). A total
of 110 cases were performed under general anesthesia, four
patients had monitored anesthesia care (MAC) and two
patients had spinal anesthesia. Prophylactic spinal drains
were placed in 19 patients (16.4%). Indications for drains
included previous aortic surgery with compromise to lum-
bar or pelvic arterial flow and need for multiple endovascu-
lar devices with anticipation of extensive thoracic intercos-
tal artery coverage. Drains were placed prior to induction of
anesthesia unless patient hemodynamic instability required
postoperative insertion. All patients were administered pre-
operative antibiotics. All patients received either a first
generation cephalosporin or clindamycin in the event of a
documented penicillin or cephalosporin allergy. Devices
used included industry-designed thoracic aortic endografts
(n 80) [GORE TAG,W. L. Gore & Associates, Flagstaff,
Ariz (n 74); COOK TX2, Cook, Inc, Bloomington, Ind
(n  4); Medtronic Talent, Medtronic/AVE, Santa Rosa,
Calif (n 2)], endovascular aortic proximal extension cuffs
(n  19) [Excluder, W. L. Gore & Associates, Flagstaff,
Ariz (n 18); AneuRx,Medtronic/AVE, Santa Rosa, Calif
(n 1)], or custom-made stent grafts (n 17) constructed
of 5 cm long stents (Gianturco Z-stents; Cook, Inc,
Bloomington, Ind) covered with ironed woven polyester
fabric (Cooley Veri Soft, Boston Scientific Corp, Oakland,
Table I. Thoracic aortic pathology treated and devices
implanted
Thoracic aortic pathology
Thoracic device
(n  80)
Aortic cuff
extender
(n  19)
Custom
(n  17)
Degenerative aortic
aneurysm
Elective 48 1 10
Rupture 9 1 1
Aortic dissection,
complicated
5 0 1
Traumatic injury 6 14 0
Pseudoaneurysm 7 0 3
Intramural hematoma 1 2 1
Penetrating aortic ulcer 2 1 1
Diverticulum of Kommerell 2 0 0NJ) delivered via a 22F delivery system. Further details ofthe custom-made graft construction and delivery have been
previously reported.9 Aortic arterial access was obtained via
percutaneous (n 45; 38.8%) or cut-down femoral arterial
approach (n 54; 46.6%), direct iliac access (n 4; 3.4%)
or iliac arterial conduit (n 8; 6.9%), direct aortic access (n
 4; 3.4%) or via the aortic arch (n 1; 0.9%). The choice
of arterial access for each patient was made based on sur-
geon preference taking into account patient anatomy and
the presence of previous groin operative intervention. All
patients underwent aortic arch and thoracic aortic angiog-
raphy before and after TEVAR to ensure satisfactory place-
ment of the device and to evaluate for endoleaks.
Follow-up. In the immediate postoperative period, all
patients were evaluated by the operating surgeon for any
complications. If any neurological deficit was suspected, a
neurologist was consulted to evaluate the patient. Major
stroke was defined as any central neurologic deficit that
persisted beyond 24 hours. Acute renal failure was defined
as any increase in the creatinine level to greater than 3.0
mg/dL with or without the need for dialysis. Respiratory
failure is defined as any patient with postoperative pneumo-
nia, prolonged intubation beyond the fifth postoperative
day, or any patient requiring tracheostomy. All patients
underwent a clinical exam and a computed tomography
angiogram (CTA) at 1 month, 6 months, 1 year, and yearly
thereafter to evaluate for endoleaks, graft migration, regres-
sion or growth of the aneurysm sac, and other late adverse
events.
RESULTS
Patient demographics. A total of 115 patients under-
went 116 primary thoracic aortic endovascular procedures
by surgeons. The disease entity and type of device used to
treat each is detailed in Table I. Thirty-five percent of the
procedures were considered emergent. The average age of
the patient cohort was 63.9 years old ( 15.9 years, range
20-93 years old). Sixty-five percent of the patients were
male. Of the total patients treated, 85% were American
Society of Anesthesiologists (ASA) class 3 and nearly 13%
of the patients were 80 years old. Baseline characteristics
are listed in Table II.
Subclavian transposition was performed in 28 patients
(24.1%) and a carotid to subclavian bypass was performed
in two patients (1.7%) with prior left internal mammary
artery coronary revascularization. The subclavian artery was
covered without revascularization in a total of seven cases.
Total arch debranching was performed in two patients
(1.7%) and hybrid elephant trunk procedures were utilized
in two patients (1.7%). Mesenteric arterial revascularization
was utilized in seven patients (6.1%). Of the mesenteric
procedures, two patients underwent celiac bypass alone
while five patients underwent multivisceral revasculariza-
tion. One patient had celiac artery coverage without prior
revascularization.
Early mortality. The 30-day mortality rate was 5.2%
(n 6) for all primary and secondary endograft procedures
(Table III). Four of six deaths followed emergent opera-
tions. As such, the 30-day mortality for emergency proce-
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aneurysm died from multisystem organ failure after a mas-
sive retroperitoneal bleed. One patient died from sepsis
after treatment of a leaking mycotic pseudoaneurysm. One
patient succumbed from multisystem organ failure after
polytrauma and repair of an acute aortic disruption. A final
patient died from unknown causes after being discharged
to an extended care facility after repair of a ruptured tho-
racic aortic aneurysm. This final patient presented with
aortic rupture and concomitant acute cholecystitis; a cho-
lecystostomy tube was placed for drainage, however, the
potential for endograft infection and rupture cannot be
excluded since no postmortem examination was per-
formed.
The remaining two deaths occurred following elective
cases. One patient died from a massive stroke on postoper-
ative day 3. The other patient, who underwent a total hip
replacement several days after the endograft procedure,
died from respiratory failure after being discharged to an
extended care facility.
Early complications. Arterial access injuries occurred
in 13 cases (11.2%) (cut-down approach [n  8], percuta-
neous approach [n 3], iliac conduit [n 2]). In general,
arterial injuries were identified and repaired during the time
of the initial procedure with either placement of iliac stents
(n 7), or reconstruction of the iliac or femoral artery (n
4). The remaining two patients with access site complica-
tions returned to the operating room for a thromboembo-
lectomy of the lower extremity. One of these patients
Table II. Demographics
Variable N %
Emergent procedure 41 35.3
Age 80 y 15 12.9
Male gender 75 64.7
ASA class 3 99 85.3
Hypertension 93 80.2
Previous CABG or PTCA 27 23.3
Congestive heart failure 9 7.8
Present or past tobacco usage 43 37.1
COPD 15 12.9
Previous CVA 6 5.2
Dialysis dependence 10 8.6
Diabetes mellitus 22 19.0
Multiple traumatic injuries 19 16.4
Previous aortic surgery 39 33.6
ASA, American Society of Anesthesiologists; CABG, coronary artery bypass
graft; PTCA, percutaneous transluminal coronary angioplasty; COPD,
chronic obstructive pulmonary disease; CVA, cerebrovascular accident.
Table III. Thirty-day major adverse events
Complication Total %
Death 6 5.2
Stroke 10 8.6
Paraplegia/paresis 3 2.6recovered without sequelae, while the other patient, whohad suffered from polytrauma, developed further limb isch-
emia, compartment syndrome, and eventual limb loss. One
other patient suffered limb loss in this series. This patient
developed heparin induced thrombocytopenia and diffuse
arterial thrombosis, eventually requiring bilateral below
knee amputations. Three patients developed significant
access site hematomas in the days after TEVAR, one re-
quired operative decompression.
Neurological complications, consisting of stroke or
spinal cord ischemia occurred in 11.2% of the patients
treated with both primary and secondary interventions
(Table III). Major stroke and paraplegia or paresis rates
were 8.6% (n  10) and 2.6% (n  3), respectively.
Strokes occurred in the middle cerebral artery distribu-
tion in five patients, in the posterior circulation in two
patients, and in a multifocal distribution in three patients.
One of the strokes occurred during a repeat intervention to
treat a proximal endoleak.
Complete paralysis from spinal cord ischemia occurred
in two patients without recovery, while one patient experi-
enced paresis and urinary incontinence. One patient who
suffered paralysis had a spinal drain placed electively prior to
TEVAR because of a history of ruptured abdominal aortic
aneurysm (AAA) repair. She was neurologically intact until
she experienced a period of bradycardia and hypotension
on postoperative day 2; despite vasopressor induced hyper-
tension and continual spinal drainage, she did not recover
neurologic function. The second patient, who suffered
paralysis, was treated emergently for aneurysm rupture and
had a spinal drain placed immediately after surgery; the
patient experienced a prolonged period of hypotension in
the perioperative period from a retroperitoneal bleed. As
mentioned earlier, this patient developed multisystem or-
gan failure and died within 2 weeks of the endograft place-
ment. The one case of paresis occurred on the fourth
postoperative day and a spinal drain was not placed; this
patient had a history of aortobifemoral bypass for treatment
of AAA.
The left common carotid artery was inadvertently cov-
ered in one case and was treated with a retrograde carotid
stent at the time of the initial procedure. Another patient
was noted to have a left common carotid artery dissection
during the procedure which also required stent placement.
Neither patient suffered short or long-term sequelae. One
patient with intentional coverage of the subclavian devel-
oped vertebral steal syndrome and underwent a late subcla-
vian transposition without complication.
Eight patients (6.9%) suffered from respiratory failure
requiring prolonged intubation or tracheostomy. The pri-
mary reason for prolonged intubation was pneumonia in
four patients. Failure to wean oxygen occurred in two
patients with severe chronic pulmonary obstructive disease.
One patient suffered a traumatic intubation requiring a
tracheostomy and one patient had hemoptysis and required
reintubation in the immediate postoperative period.
One instance of device collapse occurred in a young
trauma patient with aortic transection. The collapse was
asymptomatic and was detected on the first postoperative
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four infrarenal aortic extension cuffs within the thoracic
device.
Three patients experienced acute postoperative renal
failure. Two of them recovered renal function without the
need for dialysis. Early nonfatal adverse events are listed in
Table IV.
Follow-up. Mean follow-up with imaging of the graft
was 15 months (15 months, range 1-78 months). There
were eight patients who were lost to follow-up after their 1
month CTA, five of these were trauma patients treated for
acute aortic transection.
Late mortality. A total of 21 patients died after the
30-day perioperative period (Fig. 1). Causes of death in-
cluded coronary artery disease or heart failure (n  6),
rupture or sepsis from an infected graft (n  4), sepsis from
other causes (n  3), respiratory failure (n  3), pneumonia
with endocarditis (n  1), perforated duodenal ulcer fol-
lowing ascending arch repair (n  1), rupture awaiting
reintervention (n  1), aspiration (n  1), and unknown
causes (n  1).
Mortality due to graft infection is detailed in Table V.
The overall delayed infection rate, including two patients
who are still alive, was 5.2% (n  6). The four deaths
occurred within days to weeks after graft infection was
detected either from rupture or sepsis. Of the six grafts that
developed infectious complications, four were placed under
emergent conditions. One patient who died presented with
an acute symptomatic intramural hematoma. This patient
was receiving chemotherapy and was neutropenic at the
time of endograft placement; the specific source of the
endograft infection remains unknown. Another graft infec-
tion occurred in a patient who initially presented emer-
gently with a penetrating aortic ulcer and acute aneurysmal
degeneration; in retrospect, this may have been mycotic on
presentation. One dialysis dependent patient developed
pyuria 2 days following endograft implantation. The same
Table IV. Procedural adverse events
Complication Total %
Arterial access site injury 15 12.9
Limbs amputated 3 2.6
Access site infection 1 0.9
Acute myocardial infarction 2 1.7
Cardiac arrhythmias 4 3.4
Acute renal failure 3 2.6
Respiratory failure 8 6.9
Pulmonary embolism 2 1.7
Inadvertent branch vessel coverage 1 0.9
Branch vessel dissection 1 0.9
Visceral infarcts 2 1.7
Pancreatitis 2 1.7
Retroperitoneal hematoma 2 1.7
Access site hematoma 3 2.6
Vocal cord palsy 2 1.7
Device collapse 1 0.9
Late subclavian steal 1 0.9organisms were identified in the blood at the time of aorticinfection and subsequent death. A fourth patient who died
from graft infection a year after implantation had been
found down and uroseptic in her home just prior to admis-
sion. This graft infection was proven at autopsy.
The two surviving patients developed type I endoleaks
with subsequent aneurysm sac enlargement. One remains
under observation and one was successfully explanted. The
first, also a chronic hemodialysis patient, developed pneu-
monia after a post-TEVAR aortic valve repair. The pneu-
monia persisted for several months despite aggressive anti-
biotic therapy. On routine graft surveillance following
resolution of the pneumonia, gas was seen around the
implanted graft. Perigraft fluid samples and pulmonary
washings revealed no bacterial or fungal isolate. This pa-
tient was deemed too high risk for an explant procedure
and is currently receiving antibiotic therapy. The final pa-
tient, who is described in more detail below, underwent
emergent endograft placement for a ruptured infected
pseudoaneurysm. Following removal of the subsequently
infected endograft, the patient underwent a complete aor-
tic replacement and is recovering.
Nonfatal late complications. Nine patients devel-
oped type I or type III endoleaks (7.8%). Of the nine
patients, four were originally treated with custom-made
stent grafts (Table VI). The average time to appearance of
endoleak was 10.2 months. Seven patients underwent re-
peat operative intervention while one patient with a distal
type I leak, died from aneurysm rupture in the hospital
prior to planned operative intervention. Two patients, who
developed proximal type I endoleaks from disease progres-
sion and arch dilatation, underwent ascending arch repair
with the distal aspect of the arch graft sewn directly to the
endograft. As briefly mentioned above, another patient,
who originally underwent emergent endograft placement
for a mycotic pseudoaneurysm, had an additional stent
graft placed for a proximal endoleak with immediate satis-
factory results. However, at 1 year following the original
endograft procedure and 2months following the secondary
procedure, the patient was found to have overt graft infec-
tion with sac enlargement and recurrence of the type I leak.
This patient underwent device explantation and aortic re-
construction with an antibiotic soaked graft. Four patients
underwent additional graft insertion with satisfactory treat-
ment of the endoleak (proximal type I [n  2]; distal type
I [n 1]; type III [n 1]). One patient was found to have
a small distal type I endoleak at the conclusion of the
procedure for treatment of a ruptured aneurysm. Subse-
quent imaging and clinical follow-up revealed the asymp-
tomatic, persistent endoleak without sac enlargement. Ad-
ditionally, the patient was found to have metastatic breast
cancer and therefore further treatment of the endoleak has
not been pursued. Nine additional patients (7.8%) were
found to have type II endoleaks on surveillance imaging.
None have resulted in sac enlargement and therefore have
not been treated. Only 3 (33%) of these patients with type
II leaks have persisted beyond 1 year.
Three additional patients underwent operative inter-
vention for progression of their aortic disease in the absence
rwen
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simultaneous with coronary bypass grafting procedure for
aneurysmal degeneration of the ascending arch at seven
months. Another patient who was initially treated for a
symptomatic subacute type B dissection was noted to have
developed an asymptomatic retrograde type A dissection on
a 6-month surveillance CTA. This likely resulted from
aortic penetration by the endoprosthesis. This patient un-
derwent a conversion to a hybrid procedure with aortic arch
replacement. A third patient, originally treated for an acute
complicated dissection, developed aneurysmal degenera-
tion of the visceral segment with rupture and underwent
emergent open reconstruction and replacement of the
aorta from the endograft to the aortic bifurcation.
DISCUSSION
The natural history of untreated major thoracic aortic
pathology is a strong impetus for patients to consider
operative repair, even if they are severely compromised or
elderly. Several large series report significant morbidity
following traditional open approaches to thoracic aortic
Fig. 1. Survival of patients who undereconstruction, especially when performed under emergentcircumstances.10,11 The use of endovascular devices for the
treatment of thoracic aortic aneurysms, as well as other
off-label indications such as traumatic aortic disruptions
and dissection, have been shown to result in decreased rates
of mortality, renal failure, and paralysis in both small series
and large trials.2-4,6,7,12 This new technology, has provided
higher risk patients, originally denied treatment via conven-
tional operative repair, the opportunity to be treated with
satisfactory results. Data from this series would support
continued use of TEVAR in a high risk group, however,
our data suggest that the incidence of significant complica-
tions remains high in this patient population. Our results
are consistent with other reports with similar risk patients
noting a combined stroke, death, and paralysis/paresis rate
of 16.4%.4,5,13We identified a periprocedural mortality rate
of 5.2%, which compares favorably with the periprocedural
mortality rate in some conventional surgical series.11,14 The
combined rate of stroke, death, and paralysis/paresis for
emergent procedures in our series was 22%. In comparison,
large series of open repair quote mortality rates as high as
26%.14,15 Our midterm results with the endovascular treat-
t endovascular thoracic aortic repair.ment of thoracic aortic pathology reflect the relative high-
s; PAU
atoma
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tion. The life table analysis (Fig) indicates that a significant
portion of the patients died within 1 year of their index
procedure; the causes of which are not related to their
endograft procedure. This reflects the complex medical
problems that these patients possess and their inability to
tolerate open surgical repair. These results reinforce the
severity of illness in patients with thoracic aortic pathology
and also bring forth the question of who will reap the most
benefit from a minimally invasive method of treatment of
Table V. Delayed endograft infections
# Original endograft Indication
Elective
or
emergent
1 GORE TAG Aneurysm EL
2 Aortic cuff
extender
Intramural
hematoma
EM
3 GORE TAG Aneurysm associated
with PAU
EM
4 GORE TAG Aneurysm, ruptured EM
5 GORE TAG Pseudoaneurysm EL
6 GORE TAG Pseudoaneurysm EM
EL, Elective; EM, emergent;MSSA,methicillin sensitive staphylococcus aureu
infection.
Table VI. Endoleaks requiring operative intervention
# Endoleak type Original endograft Indicatio
1 Proximal type I GORE TAG Aneurysm
2 Proximal type I Custom Aneurysm
3 Proximal type I Custom Aneurysm
4 Type III Custom IMH
5 Distal type I Custom/hybrid
arch repair
Aneurysm
6 Distal type I GORE TAG Aneurysm
7 Proximal type I GORE TAG Mycotic
pseudoan
8 Proximal type I GORE TAG Aneurysm
9 Distal type I GORE TAG Aneurysm
EL, Elective; EM, emergent; SCA, subclavian artery; IMH, intramural hemaortic disease.The durability and effectiveness of minimally invasive
treatment of the thoracic aorta warrants discussion and
continued imaging surveillance of these devices remains
paramount.7,16,17 In our series, the rate of type I or III
endoleaks was significant at 6.9%. Many of the leaks were
early type, none required immediate conversion to open
repair, and most followed treatment with custom-made
devices. Industry-manufactured devices seem to perform
more favorably, provided they are used in the appropriate
setting. Excluding devices placed for traumatic aortic injury
e to
tion Organism Risk factors Outcome
o MSSA,
Candida
albicans
None Death,
rupture
wk Staphylococcus
epidermidis
(oxacillin
resistant)
Chemotherapy/
stem cell
transplant
Death,
sepsis
wk Streptococcus
pneumoniae
Cirrhosis Death,
rupture
o Staphylococcus
epidermidis
(oxacillin
resistant)
ESRD,
perioperative
UTI with
same
organism
Death,
rupture
o None isolated ESRD, left
sided
pneumonia
Type I
endoleak,
hospice
o Enterobacter
cloacae
Previous aortic
graft infection
Type I
endoleak,
explant
, penetrating aortic ulcer; ESRD, end stage renal disease;UTI, urinary tract
Elective or
emergent
Time since
endograft
placement Treatment
EL 1 mo Ascending aortic arch
repair
EL 36 mo GORE TAG, SCA
transposition
EL 24 mo GORE TAG
EM 9 mo Aortic cuff extender
EL 18 mo Rupture prior to planned
procedure
EL 1 mo GORE TAG, mesenteric
debranching
sm
EM 3 mo GORE TAG
EM 2 wk Ascending aortic arch
repair
EM Immediate Surveillance for sac
enlargement
.Tim
infec
12m
5
6
19 m
48 m
3 mn
eury(which would not be expected to leak), the type I and type
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custom-made devices in this series was 6.25% and 23.5%,
respectively. In midterm reports endoleak rates as high as
24% have been reported for custom-made grafts.8,16,17,20
The GORE TAG investigators report an incidence of any
endoleak at 2 years to be 9%; of these only three patients
required endovascular revision.2 The Talent thoracic regis-
try, which included 457 patients treated for various tho-
racic aortic pathology, reports a persistent primary en-
doleak rate of 9.6% with type I endoleak being the most
common and the most important risk factor for late rup-
ture.4 Other series of patients treated with industry-de-
signed thoracic stent grafts have reported rates of endoleaks
ranging between 6% and 20 %, type I being the most
common.3,7,8,12,18 Early type I leaks, defined as those
identified on completion angiography or on a 1 month
CT scan, should be expected to resolve spontaneously. As
such, a period of observation is not unreasonable. How-
ever, early leaks that persist beyond 6 months should be
treated. Type I leaks that develop late (after 6 months)
rarely resolve spontaneously and should be considered for
open or endovascular treatment.
Patients with concomitant ascending arch disease may
require even more strict surveillance. Two of our patients
developed type I endoleaks, with sac expansion, as a result
of progression of arch pathology. Demers et al did not
report graft migration in their series, but instead proposed
inadequate fixation as the contributing factor to the devel-
opment of type I endoleaks.19 They suggest that continued
aortic aneurysmal degeneration changes themorphology of
the landing zones thus making late endoleaks possible. This
would appear to be a plausible mechanism for late failure in
our series as well. These patients require intervention,
usually with open arch reconstruction incorporating the
endograft into the distal anastomosis, as these leaks would
not be expected to resolve spontaneously and most are
adjacent to the great vessels.
In patients with traumatic aortic disruption, the rate of
endoleak was 0%. Trauma patients generally have a healthy,
normal caliber, aorta with an acute tear and without aneu-
rysmal pathology. Endoleaks would not be expected to
occur in these patients and, therefore, should probably not
be included in the context of early or late complications of
TEVAR for this subgroup. In fact, all patients treated with
aortic extender cuffs for this indication in this series did not
experience any device related complications during follow-
up. The primary concern for endograft placement in a
healthy but acutely transected aorta is the possibility of
device collapse.21,22 In these young, hyperdynamic pa-
tients, when grafts are oversized relative to the aorta, there
is a risk for device collapse and distal malperfusion. We did
observe this complication in one patient with aortic tran-
section who was treated with a GORE TAG device. Nev-
ertheless, we noted a very low incidence of device related
complications in the endovascular treatment of traumatic
thoracic aortic injury. Current literature reflects the de-
creased morbidity and mortality with endograft placement
for the treatment of polytrauma patients with thoracicaortic injury, as well as a low rate of repeat intervention for
device related complications making it a preferred alterna-
tive to open surgical repair.3,23
Delayed endograft infection and subsequent type I
endoleak from presumed aortic wall degeneration was a
cause for both early and late aneurysm-related deaths in our
series. Patients in our series, who developed graft infection
within 6 weeks of device implantation, may have had a
primary aortic infection that was not recognized at the time
of initial presentation. The patients that presented with
delayed graft infection likely had seeding of their graft from
remote infections that occurred after or around the time of
the index procedure. What is evident from our experience is
that graft placement in the setting of primary aortic or
active remote infection may result in a high incidence of
endograft infection and subsequent rupture and death.
Since there are few reports of endografts placed for thoracic
aortic infections or fistulas and fewer reports of delayed
thoracic aortic graft infection, the natural history of endo-
vascular repair in the setting of infection is relatively un-
known.24,25 The treatment of a known thoracic aortic
infection with an endograft should be undertaken with
caution and perhaps should not be performed at all. If
active infection is evident at the time of device implanta-
tion, lifelong antibiotic coverage should be considered.
Similarly, late remote infections need to be promptly diag-
nosed and treated as late endograft seeding may be more
common with thoracic endoprostheses than with sewn in
grafts.
The stroke rate of 8.6% in this report is on the higher
end of the spectrum compared with other series including
those with open surgical repair.3,18,26 This may be due to
the relatively high percentage of patients treated for very
proximal disease in this series. Thoracic aortic disease that is
adjacent to the great vessels requires manipulation of the
arch with wires, catheters, and the device prior to device
deployment. This can result in disturbance or disruption of
atherosclerotic plaque within the aorta and can lead to
cerebral embolic events. This is particularly true in patients
with disease that is within close proximity to the great
vessels so caution must be exercised.
Our stroke rate was highest in the earlier part of our
series and strokes occurred in four patients who were
treated with custom-made grafts. Other authors have de-
scribed a higher incidence of stroke with the use of custom-
made devices. This is likely related to the size and stiffness
of the delivery system.17,19 The stroke rate in the second
half of our series was reduced to 2.6% after developing an
aggressive policy regarding minimal wire and catheter ma-
nipulation in the arch and routine branch vessel revascular-
ization and after we began to deploy only industry-
designed devices.
Posterior circulation strokes occurred alone or in com-
bination with anterior circulation strokes in five patients in
our series. We have previously reported our experience with
subclavian arterial revascularization in patients requiring
proximal device fixation.27 Early in our series, we identified
two patients with isolated posterior circulation strokes who
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we now routinely perform subclavian artery transposition
or carotid to subclavian bypass in patients with dominant
left vertebral arterial circulation, LIMA coronary bypass
grafts, anticipated extensive thoracic intercostal vessels cov-
erage, or when the potential exists for retrograde perfusion
of a type B dissection via a patent subclavian artery. We
suspect that this aggressive policy of arch branch recon-
struction has contributed to an improvement in stroke rate
over time and may also contribute to optimal spinal cord
perfusion.
Paraplegia and paresis rates in our series are consistent
with previous reports. Endovascular thoracic aortic repair is
associated with a decreased incidence of paraplegia, com-
pared with conventional operative repair. This complica-
tion occurred in a patient with previous abdominal aortic
surgery with hypotension, and in a patient with acute
rupture, persistent hypotensive shock and midthoracic aor-
tic coverage. This patient profile is consistent with other
series in which patients with compromised thoracic inter-
costal arterial circulation, lack of compensatory lumbar or
pelvic circulation coexisting with hypotension developed
paraplegia or paresis.8,18,28 To prevent spinal ischemia in a
high-risk subset of patients, we selectively use spinal drain-
age when technically feasible.
Our study is limited by its retrospective design and by
the fact that this is a relatively small patient cohort. In
addition, we chose not to use any standard surgical repair
patients for comparison. Despite these shortcomings, we
conclude that in certain patient populations, the endovas-
cular treatment of thoracic aortic pathology is a viable
alternative to open repair. We also conclude, however, that
like with open repair TEVAR carries significant risk in both
early and late complications.
In conclusion, advances in the endoluminal technology
used to treat thoracic aortic pathology have allowed many
patients to undergo life saving treatments with decreased
morbidity and mortality. On the other hand, it is clear that
the elderly and infirmed may not fare well, even with a
“minimally invasive” therapy. Furthermore, unlike open
surgical repair, the long-term durability of thoracic aortic
endograft remains to be seen. Long-term imaging surveil-
lance is required to monitor for endoleaks and repeat
interventions may be required if device failure or migration
should occur. Overall, TEVAR for thoracic aortic pathol-
ogy is safe and efficacious, but it is not without significant
high risk in the complex patient population who come to
endovascular repair.
The authors thank Daniel Amaranto for his assistance
with the life table analysis.
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Dr Quinones-Baldrich (Los Angeles, Calif). I would like to
congratulate Dr Brown and the vascular service at Northwestern
University for an excellent presentation of their 7-year experience
with endovascular repair of complex thoracic aortic pathology.
They have treated 111 high-risk patients with either complete
endovascular or a hybrid alternative to surgical repair. Some of
these interventions were not really minimally invasive. It is really a
new day in vascular surgery when we call an aortic debranching or
an elephant trunk part of a minimally invasive approach. They do
represent an option to what is otherwise a formidable operative
intervention. Although a comparison to standard surgical repair is
not really appropriate, the overall results support their conclusion
that endovascular repair of complex aortic pathology is a viable
alternative in the management of these difficult patients. As an
advocate of endovascular treatment to these complex cases, I
remain concerned that the overall results are not a significant
improvement over those accomplished by experienced surgeons
performing open repair.
A combined stroke and paraplegia incidence of about 12%
must be reduced if we are to continue to offer endovascular repair
as a better alternative. Keep in mind that their series includes
patients with penetrating aortic ulcer, intramural hematoma, trau-
matic injuries, and other pathology in which the risk of these
complications is relatively low for open surgical repair. Spinal
catheter drainage was used in 17 patients. In several of these
patients the indication for spinal drainage was related to the
extensive coverage of the descending thoracic aorta. In the rest, the
indication was previously aortic surgery. There were 38 patients in
their series that had prior aortic surgery, which leads to my first
question: why was spinal catheter drainage not used in all patients
with prior aortic surgery? What was the incidence of paraplegia in
those patients with prior aortic surgery in whom spinal catheter
drainage was not used?
The 30-day mortality of 5.4% as reported in this series is
excellent, particularly when one considers that only about half of
the cases were performed electively. On the other hand, the late
mortality, which the authors report represents the 1-year mortality
as delineated in the manuscript, was about 23% as calculated by
nonactuarial methods. This is of concern. I have attempted to
calculate their cumulative mortality based on the information in
the manuscript, and by my estimate, the 1-year cumulative mor-
tality approaches 30%. This does not take into account the addi-
tional interventions and other complications that required treat-
ment. Keep in mind that a high 1-year mortality tends to improve
the calculation of incidence of nonfatal events because survivors
tend to have fewer of these events. Their follow-up ranges from 1calculated actuarial survival for their entire series? What is the
1-year mortality as calculated by these actuarial methods?
Early and mid-term endograft infection was uniformly lethal.
The authors have attempted to identify factors that would increase
the risk of infection as a complication. Could the authors tell us
which risk factors or findings on imaging they consider a contra-
indication for endovascular repair?
Several patients in their series underwent successful open
surgical repair after a failed endovascular approach, which leads me
to my final question: do the authors recommend primary open
repair in certain cases? What are their criteria to recommend open
repair as opposed to an endovascular treatment?
I would like to thank the society for the privilege of discussing
this excellent experience and the authors for providing me with a
copy of the manuscript prior to the meeting.
Dr Brown. Thank you again to the society for allowing us the
opportunity to present our results for the treatment of thoracic
aortic pathology. Many thanks as well to Dr Quinones for review-
ing the manuscript and putting forth these excellent questions.
Our 30-day mortality rate of 5.4% is comparable to other
reports for the endovascular treatment of thoracic aortic disease;
however, it is true that we did see a high rate of death in our series
within 1 year of their index procedure. The cause of death was
related to the patient’s comorbidities or graft infection. We treated
a high-risk group of patients with various types of thoracic aortic
pathology. Those patients who were not part of an industry-
sponsored trial were treated even though they may have had a
limited life expectancy from other disease states. We managed
these patients based upon the supposition that we could treat their
thoracic aortic pathology in a less morbid manner than we could
with open surgery. What is evident is that patients with thoracic
aortic disease, especially those in need of an emergency operation,
are amongst the highest risk patients that we care for. Even a
minimally invasive operation is not without significant risks. We
will include in ourmanuscript an analysis of our survival in the form
of a life table.
With regards to our stroke rate, we acknowledge that 9% is,
indeed, a high number when compared to other published series.
We looked at the relationship of stroke to type of device deployed
and also to the patient’s cerebral artery anatomy. We found a
higher incidence of stroke in patients in which a custom-made graft
was deployed. The large and inflexible delivery systems required for
custom-made graft deployment cause excessive manipulation of
the aortic arch, which may result in more embolic events from
disruption of aortic atherosclerotic plaque and debris. This is
supported by other reports that have noted similar rates of stroke
when custom-made grafts are used. In our patients in whom the
less bulky industry-designed devices were placed, our stroke rate
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patients had coverage of a left subclavian artery that gave origin to
dominant left vertebral artery, strokes occurred. We now routinely
transpose or bypass the left subclavian artery in almost all of our
patients prior to intentional coverage, but especially in patients
with a dominant left vertebral artery. This approach has resulted in
a decrease in the incidence of posterior circulation stroke. As
technology continues to improve we predict the incidence of
stroke may decrease further.
In terms of paralysis, our results are on par with other reports
of endovascular thoracic aortic repair. We put in spinal drains in
approximately 16% of our patients. It is true that 34% of our
patients had previous aortic surgery. The decision to place drains
was based on surgeon preference and also depended on the emer-
gency nature of the operation. Even though we do not use a
standard algorithm for placement of spinal drains, we have turned
toward placing prophylactic spinal drains in those patients in which
extensive intercostal artery coverage is anticipated and/or in the
patient with compromised pelvic and lumbar arterial flow from
previous aortic repair. In the latter half of our series, spinal drains
were placed more frequently than in the beginning of our experi-
ence.
To address your question about predicting endograft infec-
tion, we are still trying to sort this one out. Four out of the six
patients who developed delayed infection had endovascular aortic
repair under emergency conditions such as rupture or acute expan-
sion with pain. In our series of patients, there were no clear-cut
imaging findings that indicated primary aortic infection. In one
patient, we did suspect an underlying remote infection from a prior
open intervention that was present at the time of deployment. Theremaining patients either had presumed device seeding from sys-
temic infections that developed later or had unknown underlying
primary aortic infections, which was what brought them to emer-
gency repair in the first place. We caution against the use of these
grafts in the face of a known infection since our experience has
shown that delayed endograft infection is a highly morbid condi-
tion and in our series led to death, rupture, and/or type I endoleak
in all cases. We administer antibiotic prophylaxis before every case
and aggressively treat any postoperative infection in order to
prevent possible delayed seeding of the endograft.
To address the final question regarding criteria for open repair
vs endovascular repair, we choose the operation that is bet suited
for the patient’s anatomy and clinical condition. Patients with
anatomy suitable for treatment with an endograft and who were
also considered relatively high risk for open repair were more likely
to undergo endovascular repair. We concede that one of the
limitations of this paper is the fact that we do not have an open
surgical patient group for comparison. Many of our degenerative
aneurysm patients were treated as part of a clinical trial, while other
patients with other pathologies were treated with a minimally
invasive approach because they were not thought to be candidates
for open conventional repair either due to medical comorbidities
or due to the clinical situation.
While there certainly are limits to the benefit gained with the
endovascular management of thoracic aortic pathology and even
though many patients require secondary interventions, the endo-
vascular treatment of thoracic aortic pathology is efficacious and
has decreased perioperative morbidity and mortality when com-
pared to open surgical repair, especially in high-risk patients.
